Research Reports | Market Assessment
October 2019

Asthma – Emerging Therapies – Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Table of contents

  • Asthma - Emerging Therapies - Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)
    • Asthma and COPDu00a0Emerging Therapies Salmeterol / Fluticasone Genericu00a0US Wave 2 (October 2019)
Ajay Puri, M.B.A.
Ajay Puri, M.B.A.

Ajay Puri, M.B.A. (Pharma.), Senior Healthcare Research & Data Analyst, Immune and Inflammation. He has expertise in Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus. Prior to joining Clarivate, he worked as a knowledge management associate at ZS Associates, where he conducted competitive assessment, company and product profiling, and other projects. He holds a bachelor’s degree in pharmacy and an M.B.A. in marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports